

Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

A32 Monoclonal Antibody Fusion Protein for Use as HIV Inhibitors and Vaccines

Dimiter S. Dimitrov and Mei-yun Zhang (NCI).
U.S. Provisional Application No. 60/618,820 filed 14 Oct 2004 (HHS Reference No. E-302-2004/0-US-01).
Licensing Contact: Sally Hu; 301/435-5606; hus@mail.nih.gov.

The invention provides composition claims of a fusion protein, which comprises an antigen binding portion of a human antibody called A32 and one of the following: (a) An antigen-binding portion of a second antibody that binds to an epitope of an envelope protein (*i.e.*, gp120) of a human immunodeficiency virus (HIV) that is exposed upon the HIV binding to a CD4 receptor, (b) an immunogenic portion of an envelope protein of a HIV such as gp120, or (c) a soluble CD4 (sCD4) polypeptide capable of binding to HIV. The invention also provides the method claims to use the above fusion proteins as inhibitors of HIV infection and those containing gp120 such as A32-gp120 as vaccine immunogens for the treatment and prevention of HIV. Further development of the fusion proteins may yield novel therapies and methods in the prevention of mother-to-child transmission of HIV, treatment of accidental exposure to HIV, and chronic infection in patients with resistance to current therapies.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

Plasmid and Viral Vectors Expressing a Microtubule-Directed Fluorescent Fusion Protein for Cellular Imaging

Dr. Michael J. Iadarola *et al.* (NIDCR).
HHS Reference No. E-153-1999/0—
Research Tool.
Licensing Contact: Marlene Shinn-Astor; 301/435-4426; shinnm@mail.nih.gov.

This technology is a fluorescent protein for discrete tracing of intra- and intercellular connections and for sorting and isolation of cells. This recombinantly engineered protein can be expressed from viral vectors for use in living animals and in *ex vivo* situations involving primary cultured

cells or from a plasmid for use in cell lines. The new protein consists of a fusion between the tau protein, which binds to microtubules, and enhanced green fluorescent protein (tau-eGFP). When cloned into adenovirus, the contrast can be used for transducing primary cultures for *ex vivo* gene therapy and for use as an anterograde tracer in brain circuit analysis. These uses can be a valuable research tool to help scientists find out how the brain works, investigate Alzheimer's disease, and to identify specific cells for treating disease via cell transplantation.

Dated: July 19, 2005.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 05-15348 Filed 8-2-05; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President's Cancer Panel.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), title 5 U.S.C., as amended, because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

Name of Committee: President's Cancer Panel.

Date: August 25, 2005.

Open: August 25, 2005, 8 a.m. to 2:30 p.m.
Agenda: Cancer Survivorship; Treatment Records, Follow-up, and HIPPA.

Place: The Washington Marriott Hotel, 1221 22nd Street, NW., Washington, DC 20037.

Closed: August 25, 2005, 3 p.m. to 5 p.m.
Agenda: The Panel will discuss the treatment records and follow-up care plans.

Place: The Washington Marriott Hotel, 1221 22nd Street, NW., Washington, DC 20037.

Contact Person: Abby Sandler, Ph.D., Executive Secretary, National Cancer

Institute, National Institutes of Health, Building 6116, Room 212, 6116 Executive Boulevard, Bethesda, MD 20892. (301) 451-9399.

Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's Home page: <http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS).

Dated: July 26, 2005.

Anthony M. Coelho, Jr.,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05-15243 Filed 8-2-04; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Genetics of Alaska Natives.

Date: August 16, 2005.

Time: 9 a.m. to 11 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 7214, Bethesda, MD 20892. (Telephone conference call.)